Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Peptide and Oligonucleotide CDMO Market

Peptide and Oligonucleotide CDMO Market Share

Report ID: GMI8502
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Peptide and Oligonucleotide CDMO Market Share

The competitive landscape of the peptide and oligonucleotide CDMO industry is characterized by the presence of established pharmaceutical companies vying for market share. Key market players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion, research and development, service diversification, and regulatory compliance to maintain a competitive edge in the market.

Peptide and Oligonucleotide CDMO Market Companies

Prominent players operating in the peptide and oligonucleotide CDMO industry are as mentioned below:

Aurigene Pharmaceutical Services Ltd.
Bachem Group
CordenPharma International
Creative Peptides
Curia Global, Inc.
EUROAPI S.A.
Merck KGaA
PolyPeptide Group
STA Pharmaceutical Co. Ltd.
Sylentis, S.A.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of peptide and oligonucleotide CDMO was reached USD 2.3 billion in 2023 and is set to grow at a 12.1% CAGR from 2024 to 2032, driven by the increasing demand for personalized medicine and targeted therapies, requiring customized peptides and oligonucleotides.

Peptide and oligonucleotide CDMO from the peptide segment generated USD 1.5 billion in revenue in 2023 and is estimated to witness high demand through 2032, attributed to the increasing demand for peptide-based drugs in oncology, metabolic disorders, and infectious diseases.

North America peptide and oligonucleotide CDMO industry accounted for 44.9% revenue share in 2023 and is projected to reach USD 2.8 billion by 2032, owing to the presence of well-established pharmaceutical and biotechnology industries, advanced healthcare infrastructure, and strong regulatory framework.

Some of the top peptide and oligonucleotide CDMO companies are Aurigene Pharmaceutical Services Ltd., Bachem Group, CordenPharma International, Creative Peptides, Curia Global, Inc., EUROAPI S.A., Merck KGaA, PolyPeptide Group, STA Pharmaceutical Co. Ltd., and Sylentis, S.A.